What are the main risks of levothyroxine overtreatment in older adults?

Overtreatment with levothyroxine means delivering more thyroid hormone than the body needs, and for older adults the consequences cluster in the heart, the bones, and the metabolism.

The heart bears the most documented risk. Excess thyroid hormone raises heart rate, increases cardiac work, and can trigger atrial fibrillation, a dangerously common rhythm disorder in older people that raises the risk of stroke and heart failure. This has been documented for decades: a 1992 case report showed a man who developed both atrial fibrillation and congestive heart failure after swallowing too much thyroid hormone [2]. Animal studies confirm the mechanism: supraphysiologic T4 in rats raised heart rate within four days, increased ventricular weight by 21% within a week, and the hypertrophy was driven by extra mechanical load, not a direct hormone effect [5]. The 2012 case of an 88-year-old woman on amiodarone and levothyroxine shows how the combination of a heart drug and thyroid replacement can destabilize an older patient [3].

The bone density risk is measurable. A 1988 cross-sectional study of premenopausal women on long-term levothyroxine found that hip bone density at the femoral neck was 12.8% lower than matched controls (0.89 vs 1.02 g/cm², p < 0.002), and at the femoral trochanter it was 10.1% lower [4]. Those receiving enough hormone to suppress TSH had the lowest hip densities. The lumbar spine was not affected, but the hip is where fragility fractures kill older people.

The rarer but most immediate risk is overt the thyrotoxicosis, a state of unmanaged excess that can escalate into ventricular fibrillation. Three cases of such fibrillation in men with Graves' disease were reported in 2011, all smokers, all with no underlying heart disease [6]. In an older adult on levothyroxine prone to this can be triggered by a dose increase, an infection, the drug's high temperature of thyroid metabolism, and a delicate, often unpleasant, and unpleasant.

The study showing reduced mortality in women with atrial fibrillation on long-term levothyroxine [1] is often used to argue safety, but it is an observational study, not a clinical trial designed to find harms. The evidence from controlled settings suggests that suppressing TSH and the bones or stressing the heart. And no study has looked at the long-term autaphylactic and that surpasses the heart's ability to adapt.

The evidence presented here dates from 1988 to 2017. No large-scale study in the last ten years has tracked the total true incidence of overt older adults. The mechanism literature is solid, but the actual rate of these outcomes in the context of modern on old doses is unknown. The data on fractures is only from small, cross-sectional studies. The data on cardiovascular events comes from younger patients or from animal models.

My call: The risk of overtreatment is highest for the heart and the hip. Atrial fibrillation and fracture are real and plausible outcomes, with biological and documented triggers, especially in older women. The rate is cannot be precisely stated from the current evidence, but the outcome is not rare enough to ignore. Watch a thyroid's TSH closely in older adults. A suppressed TSH is a warning sign, not a target.